Bayer's mineralocorticoid receptor antagonist (MRA) Kerendia hit the mark as a treatment for a common form of heart failure in the FINEARTS-HF study, setting up regulatory approvals, but th
Novartis has a long way to go to make its twice-yearly cholesterol-lowering drug Leqvio the multi-billion-dollar blockbuster it is predicting – but took another step along that road today.
A virtual voice assistant that calls patients after heart procedures can allow them to be discharged from hospital earlier and identify patients who may need follow-up interventions, accord
A judge in the US has denied an attempt by Novartis to stop MSN Pharmaceuticals from launching a generic version of heart failure blockbuster Entresto.
At the start of this year, Bayer said there were two important trial readouts for the company to deliver near-term growth this year as it rebuilds its pipeline – and both have now delivered
Shares in NewAmsterdam Pharma were sliding today after it reported a phase 3 trial of obicetrapib that met its primary objective but didn't meet the expectations of some analysts and invest
In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Luca Quagliata, Vice President and Global Head of Medical and Scientific Affairs at Thermo Fisher Scientific, a company